The IMBG test for evaluating the pharmacodynamic response to immunosuppressive therapy in kidney transplant patients: current evidence and future applications
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Pascual, Julio (Pascual Santos)
- dc.contributor.author Crespo Barrio, Marta
- dc.contributor.author Portolés, José
- dc.contributor.author Jimenez, Carlos
- dc.contributor.author Ortega-Carrión, Álvaro
- dc.contributor.author Diez, Teresa
- dc.contributor.author Portero, Isabel
- dc.date.accessioned 2024-04-24T06:42:20Z
- dc.date.available 2024-04-24T06:42:20Z
- dc.date.issued 2023
- dc.description.abstract Immunosuppressive drugs are widely used to prevent rejection after kidney transplantation. However, the pharmacological response to a given immunosuppressant can vary markedly between individuals, with some showing poor treatment responses and/or experiencing serious side effects. There is an unmet need for diagnostic tools that allow clinicians to individually tailor immunosuppressive therapy to a patient’s immunological profile. The Immunobiogram (IMBG) is a novel blood-based in vitro diagnostic test that provides a pharmacodynamic readout of the immune response of individual patients to a range of immunosuppressants commonly used in kidney transplant recipients. Here, we discuss the current approaches used to measure the pharmacodynamic responses of individual patients to specific immunosuppressive drugs in vitro, which can then be correlated with patient’s clinical outcomes. We also describe the procedure of the IMBG assay, and summarize the results obtained using the IMBG in different kidney transplant populations. Finally, we outline future directions and other novel applications of the IMBG, both in kidney transplant patients and other autoimmune diseases.
- dc.description.sponsorship The proof-of-concept and TRANSBIO (BHP-IBG-2017-01) IMBG studies were funded by a competitive grant from the European Commission (SME Instrument–Phase II). Project: TRANSBIO (Id 733248) “Cellular BIOtechnology for prognosis and monitoring in renal TRANSplantation”. See https://cordis.europa.eu/project/id/733248. Julio Pascual is supported by grants ISCIII FIS-FEDER 19/0037 and Redinren RD16/0009/0013. Marta Crespo is supported by grants ISCIII FIS-FEDER 20/0090 and Redinren RD16/0009/0013.
- dc.format.mimetype application/pdf
- dc.identifier.citation Pascual J, Crespo M, Portoles J, Jimenez C, Ortega-Carrion A, Diez T, et al. The IMBG test for evaluating the pharmacodynamic response to immunosuppressive therapy in kidney transplant patients: current evidence and future applications. Int J Mol Sci. 2023 Mar 8;24(6):5201. DOI: 10.3390/ijms24065201
- dc.identifier.doi http://dx.doi.org/DOI: 10.3390/ijms24065201
- dc.identifier.issn 1422-0067
- dc.identifier.uri http://hdl.handle.net/10230/59875
- dc.language.iso eng
- dc.publisher MDPI
- dc.relation.ispartof Int J Mol Sci. 2023 Mar 8;24(6):5201
- dc.relation.projectID info:eu-repo/grantAgreement/EC/H2020/733248
- dc.rights © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.rights.uri http://creativecommons.org/licenses/by/4.0/
- dc.subject.keyword Transplant rejection
- dc.subject.keyword Immunosuppressive therapy
- dc.subject.keyword Infection
- dc.subject.keyword Cellular pharmacodynamics
- dc.subject.keyword Immune cell assay
- dc.title The IMBG test for evaluating the pharmacodynamic response to immunosuppressive therapy in kidney transplant patients: current evidence and future applications
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/publishedVersion